Key Takeaway: Cognition Therapeutics has reported its financial results for the first quarter of 2024. The article primarily focuses on the company's financial performance and business updates. However, it does not provide specific details about the results or any significant developments. The content is largely informational regarding the company's website policies.
Price reaction · baseline $1.98 (2024-05-07T18:18:00.000Z) · hit during market hours · clean, no other CGTX news in the window
day 0 close · peak
-3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.